lgg101

Leonard Gomella, MD

Contact Dr. Gomella

1025 Walnut Street
Suite 1112
Philadelphia, PA 19107

(215) 955-6961
(215) 923-1884 fax

Most Recent Peer-reviewed Publications

  1. Prevalence and Characteristics of Patients with Suspected Inherited Renal Cell Cancer: Application of the ACMG/NSGC Genetic Referral Guidelines to Patient Cohorts
  2. Editorial Comment
  3. Decipher correlation patterns post prostatectomy: Initial experience from 2 342 prospective patients
  4. Clinical Influences in the Multidisciplinary Management of Small Renal Masses at a Tertiary Referral Center
  5. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report
  6. An Approach Using PSA Levels of 1.5‚ÄČng/mL as the Cutoff for Prostate Cancer Screening in Primary Care
  7. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer
  8. Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk
  9. Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study
  10. Editorial Commentary
  11. VPAC1 targeted 64Cu-TP3805 positron emission tomography imaging of prostate cancer: Preliminary evaluation in man
  12. Big data equals big challenges for prostate cancer
  13. Prostate, breast and ovarian cancer genetic risk assessment: Connecting the dots
  14. TV drug commercials: Keeping physicians informed
  15. How I Do It: Genetic counseling and genetic testing for inherited prostate cancer
  16. Dosing, administration, and safety of radium-223: How i do it
  17. Suppression of progranulin expression inhibits bladder cancer growth and sensitizes cancer cells to cisplatin
  18. Radical Retropubic Prostatectomy
  19. Punishing Physicians for PSA Screening
  20. Survival outcomes of sipuleucel-T phase III studies: Impact of control-arm cross-over to salvage immunotherapy